These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 33738773)

  • 1. Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Type 1 Diabetes Mellitus on Body Composition and Glucose Variabilities: Single-Arm, Exploratory Trial.
    Baba Y; Ishibashi R; Takasaki A; Ito C; Watanabe A; Tokita M; Meguro M; Harama T; Hirayama K; Yamamoto T; Nakamura S; Koshizaka M; Maezawa Y; Uchida D; Okajima F
    Diabetes Ther; 2021 May; 12(5):1415-1427. PubMed ID: 33738773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing Patient Satisfaction Following Sodium Glucose Co-Transporter 2 Inhibitor Treatment for Type 1 Diabetes Mellitus: A Prospective Study in Japan.
    Ishibashi R; Baba Y; Kakinuma K; Takasaki A; Hiraga C; Harama T; Yamamoto T; Nakamura S; Koshizaka M; Maezawa Y; Uchida D; Okajima F
    Diabetes Ther; 2021 Jan; 12(1):453-460. PubMed ID: 33237553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
    Takasu T; Hayashizaki Y; Hirosumi J; Minoura H; Amino N; Kurosaki E; Takakura S
    Biol Pharm Bull; 2017; 40(5):675-680. PubMed ID: 28458353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Short-term Glucose Lowering Effects of Sodium-glucose Cotransporter 2 Inhibitors Confirmed by Flash Glucose Monitoring in Two Outpatients with Type 1 Diabetes].
    Habu M; Okada Y; Kurozumi A; Tanaka Y
    J UOEH; 2020; 42(4):359-364. PubMed ID: 33268615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Tofogliflozin and Ipragliflozin for Patients with Type-2 Diabetes: A Randomized Crossover Study by Flash Glucose Monitoring.
    Kawaguchi Y; Sawa J; Kumeda Y
    Diabetes Ther; 2020 Dec; 11(12):2945-2958. PubMed ID: 33063270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors.
    Kuchay MS; Farooqui KJ; Mishra SK; Mithal A
    Adv Exp Med Biol; 2021; 1307():213-230. PubMed ID: 32006266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Effectiveness of Oral Hypoglycemic Agents for Glycemic Control and Glycemic Variability in Patients with Type 2 Diabetes Mellitus: Using Flash Glucose Monitoring.
    Venkatachalapathy P; Mohandoss KKDA; Munisamy M; Sellappan M
    Curr Diabetes Rev; 2024 Jan; ():. PubMed ID: 38310479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. There is a Close Association Between the Recovery of Liver Injury and Glycemic Control after SGLT2 Inhibitor Treatment in Japanese Subjects with Type 2 Diabetes: A Retrospective Clinical Study.
    Kinoshita T; Shimoda M; Sanada J; Fushimi Y; Hirata Y; Irie S; Obata A; Kimura T; Hirukawa H; Kohara K; Tatsumi F; Kamei S; Nakanishi S; Mune T; Kaku K; Kaneto H
    Diabetes Ther; 2018 Aug; 9(4):1569-1580. PubMed ID: 29931506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of sodium-glucose co-transporter-2 inhibitors on the levels of serum asprosin in patients with newly diagnosed type 2 diabetes mellitus.
    Jiang A; Feng Z; Yuan L; Zhang Y; Li Q; She Y
    Diabetol Metab Syndr; 2021 Mar; 13(1):34. PubMed ID: 33766125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.
    Arase Y; Shiraishi K; Anzai K; Sato H; Teramura E; Tsuruya K; Hirose S; Deguchi R; Toyoda M; Mine T; Kagawa T
    Clin Drug Investig; 2019 Jul; 39(7):631-641. PubMed ID: 30993553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospect of Sodium-Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes.
    Yang Y; Zhao C; Ye Y; Yu M; Qu X
    Front Endocrinol (Lausanne); 2020; 11():190. PubMed ID: 32351447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Relationship between Increases in Morning Spot Urinary Glucose Excretion and Decreases in HbA
    Kim SR; Lee YH; Kang ES; Cha BS; Lee BW
    Diabetes Ther; 2017 Jun; 8(3):601-609. PubMed ID: 28332143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis.
    Wang H; Yang J; Chen X; Qiu F; Li J
    Clin Ther; 2019 Feb; 41(2):322-334.e11. PubMed ID: 30711143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term observation of estimated fluid volume reduction after the initiation of ipragliflozin in patients with type 2 diabetes mellitus: a sub-analysis from a randomized controlled trial (PROTECT).
    Tanaka A; Imai T; Toyoda S; Sugimoto K; Yoshida R; Furuta M; Node K;
    Diabetol Metab Syndr; 2023 Jul; 15(1):152. PubMed ID: 37415229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Efficacy and Safety of Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors in Real-World Clinical Practice: Potential Cautionary Use in Elderly Patients with Type 2 Diabetes (T2D).
    Lee DH; Oh JH; Jeon HJ; Oh TK
    Diabetes Ther; 2024 Jul; 15(7):1615-1626. PubMed ID: 38771472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
    Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
    Liu B; Wang Y; Zhang Y; Yan B
    Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
    Rahelić D; Javor E; Lucijanić T; Skelin M
    Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.